Hospital
Hancock Regional Hospital
Hancock Regional Hospital was paid $5.81M by Medicaid between Jan 2018 and Nov 2024, across 90 billing codes. Its largest line is 99283, emergency room visit (moderate) — 42% of everything it billed.
33Billing provider infoHANCOCK REGIONAL HOSPITAL
GREENFIELD, IN 46140
GREENFIELD, IN 46140
33aNPI1467485003assigned 07/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.81M
24GClaims123,685
24DCodes billed90
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#44 of 69
Median peer was paid$9.76M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,639 | $321K | |
| 2019 | 15,107 | $515K | |
| 2020 | 11,873 | $585K | |
| 2021 | 18,607 | $854K | |
| 2022 | 22,572 | $1.28M | |
| 2023 | 20,471 | $1.21M | |
| 2024incomplete | 15,416 | $1.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 42% | 20,113 | 17,423 | $2.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 9,565 | 8,100 | $1.75M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.0% | 5,913 | 4,431 | $405K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 5.1% | 1,138 | 483 | $298K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 1,024 | 821 | $103K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 1,711 | 1,374 | $99K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 21,453 | 15,921 | $78K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 72 | 54 | $65K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 543 | 492 | $63K |
| 80053 | Comprehensive metabolic panel | 1.1% | 12,071 | 9,053 | $62K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 564 | 458 | $52K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,083 | 20,317 | $41K |
78 more codes
| 99285 | Emergency room visit (most serious) | <1% | 418 | $37K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,160 | $34K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,157 | $34K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 140 | $24K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 230 | $22K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 323 | $20K |
| 73630 | <1% | 504 | $20K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 109 | $18K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 46 | $17K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 131 | $13K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 237 | $12K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 982 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 247 | $10K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 218 | $10K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 89 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 159 | $7K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 20 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,345 | $4K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 101 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 170 | $3K |
| 80061 | Lipid panel | <1% | 220 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 38 | $2K |
| 83605 | <1% | 342 | $2K | |
| 81001 | <1% | 1,096 | $2K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 13 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 55 | $2K |
| 87088 | <1% | 321 | $2K | |
| 83874 | <1% | 364 | $2K | |
| 81003 | <1% | 2,170 | $2K | |
| 84484 | <1% | 369 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 78 | $1K |
| 97597 | <1% | 29 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 205 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 95 | $1K |
| 84439 | <1% | 186 | $1K | |
| 82553 | <1% | 370 | $1K | |
| 81025 | <1% | 154 | $955.45 | |
| 85027 | <1% | 1,395 | $943.43 | |
| 87660 | <1% | 51 | $905.25 | |
| 87510 | <1% | 51 | $865.15 | |
| 87480 | <1% | 51 | $865.15 | |
| 83690 | <1% | 232 | $823.24 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 53 | $731.15 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 14 | $724.23 |
| 86803 | <1% | 41 | $526.99 | |
| 80306 | <1% | 31 | $512.71 | |
| 86703 | <1% | 41 | $506.30 | |
| 82728 | <1% | 66 | $467.51 | |
| 86592 | <1% | 100 | $341.85 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 18 | $305.84 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 18 | $294.21 |
| 83550 | <1% | 67 | $282.30 | |
| 87081 | <1% | 49 | $278.86 | |
| 83540 | <1% | 67 | $208.98 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 880 | $183.54 |
| 87808 | <1% | 12 | $183.02 | |
| 87905 | <1% | 12 | $146.27 | |
| 86747 | <1% | 22 | $145.36 | |
| 86762 | <1% | 23 | $142.56 | |
| A9270 | Non-covered item or service | <1% | 1,324 | $134.80 |
| 87340 | <1% | 29 | $110.61 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 800 | $106.12 |
| 87220 | <1% | 12 | $51.11 | |
| 86850 | <1% | 23 | $40.72 | |
| 85379 | <1% | 12 | $30.54 | |
| J3490 | Unclassified drugs | <1% | 27 | $11.59 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 48 | $2.27 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 91 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 36 | $0.00 |
| G0435 | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening | 0% | 18 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 14 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 147 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 257 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 278 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 43 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 47 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 22 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, PEARSON (CFO & VP FINANCE)